Measurable residual disease testing for personalized treatment of acute myeloid leukemia

• This review summarizes – with the practicing hematologist in mind – the methods used to determine measurable residual disease (MRD) in everyday practice with some future perspectives, and the current knowledge about the prognostic impact of MRD on outcome in acute myeloid leukemia (AML), excluding acute promyelocytic leukemia. Possible implications for choice of MRD method, timing of MRD monitoring, and guidance of therapy are discussed in general and in some detail for certain types of leukemia with specific molecular markers to monitor, including core binding factor (CBF)-leukemias and NPM1-mutated leukemias.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Nyckelord

Acute myeloid leukemia

CBF leukemia

CBFB-MYH11

flow cytometry

inv(16)

measurable residual disease

multicolor flow cytometry

NPM1

personalized treatment

RUNX1-RUNX1T1

t(16;16)

t(8;21)

Publikations- och innehållstyp

for (ämneskategori)

ref (ämneskategori)